BioTime (NYSEAMERICAN:BTX) Trading Down 7.2%

BioTime, Inc. (NYSEAMERICAN:BTX) fell 7.2% during mid-day trading on Wednesday . The company traded as low as $0.66 and last traded at $0.69, 803,000 shares changed hands during trading. An increase of 12% from the average session volume of 719,479 shares. The stock had previously closed at $0.74.

Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new stake in BioTime during the second quarter valued at approximately $26,000. Creative Planning raised its holdings in shares of BioTime by 52.2% during the second quarter. Creative Planning now owns 227,392 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 77,978 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of BioTime by 10.2% during the second quarter. Citadel Advisors LLC now owns 114,117 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 10,570 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in shares of BioTime during the second quarter worth $368,000. Finally, Zacks Investment Management purchased a new position in shares of BioTime during the second quarter worth $85,000.

BioTime Company Profile (NYSEAMERICAN:BTX)

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Further Reading: How analysts view the yield curve

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.